Mantle cell lymphoma (MCL) is a rare and usually aggressive subtype of non – Hodgkin lymphoma (NHL) affecting the outer edge (mantle) of the lymph nodes. MCL most commonly affects men over the age of 50 years and accounts for approximately 5% to 10% of all NHL cases.1 As MCL is rare, limited information is available on patient characteristics, outcomes, treatment and management strategies of patients with the condition.
Our client’s challenge
In this case study, our client wanted to know if and how treatment patterns for MCL had changed over the past ten years, since the introduction of newer novel agents. The analysis, focused specifically on current treatment patterns, time to next treatment (TTNT), duration of treatment, overall survival (OS) and outcomes of patients with MCL. The insights from this analysis would help our client understand the real-world utilisation of medicines in the Australian treatment setting and dictate medical engagement, access communications and launch planning.
……………. Download full case study here: https://bit.ly/45LgYZ2
Speak to Prospection today to learn more about about the Prospection platform and its analytics capabilities.